DOCMORRIS AG CHF 95 Mio.
Zur Rose Group AG / Schlagwort(e): Kapitalmaßnahme
Endgültige Zuteilung der Wandelanleihe der Zur Rose im Betrag von etwa CHF 95
Mio.
13.09.2022 / 09:25 CET/CEST
------------------------------------------------------------
Not for release, publication or distribution in whole or in part in or into the
United States, Canada,
Australia or Japan or any other jurisdiction in which the distribution or
release would be unlawful.
Frauenfeld, 13. September 2022
Medienmitteilung
Endgültige Zuteilung der Wandelanleihe der Zur Rose im Betrag von etwa CHF 95
Mio.
Nach der erfolgreichen Platzierung und vorläufigen Zuteilung einer
unbesicherten Wandelanleihe der Zur Rose Group AG (die "Gesellschaft" oder "Zur
Rose Group") am 1. September 2022 im Betrag von etwa CHF 95 Mio. mit einer
Fälligkeit im Jahr 2026 und nach Ablauf des Zeitraums zur Ausübung der
Vorwegzeichnungsrechte am 12. September 2022 erfolgte heute die endgültige
Zuteilung der Wandelanleihe. Details der endgültigen Zuteilung werden den
teilnehmenden institutionellen Investoren heute mitgeteilt.
Bis zum 12. September 2022, 12:00 Uhr mittags MESZ wurden 1'993'560
Vorwegzeichnungsrechte durch dazu berechtigte Aktionäre ausgeübt. Dies
entspricht 16'613 Wandelanleihen (etwa 17.5% des gesamten Ausgabevolumens im
Betrag von etwa CHF 95 Mio.). Infolgedessen wurden die bisher vorläufig
erfolgten Zuteilungen an die institutionellen Investoren, die am
Bookbuilding-Verfahren am 1. September 2022 teilgenommen haben, pro rata
gekürzt ("Clawback"). Im Ergebnis erhielten diese institutionellen Investoren
eine endgültige Zuteilung von Wandelanleihen im Gesamtbetrag von etwa CHF 78.4
Mio., während anspruchsberechtigten Aktionären nach Ausübung ihrer
Vorwegzeichnungsrechte Wandelanleihen im Gesamtbetrag von etwa CHF 16.6 Mio.
endgültig zugeteilt wurden.
BofA Securities, Goldman Sachs Bank Europe SE und die UBS AG agierten als
gemeinsame Bookrunner für die Wandelanleihe.
Baker McKenzie agierte als rechtliche Beraterin der Zur Rose Group.
Kontakt für Analysten und Investoren
Dr. Daniel Grigat, Head of Investor Relations
Email: ir@zurrose.com, Telefon: +41 58 810 11 49
Kontakt für Medien
Lisa Lüthi, Group Director Communications
Email: media@zurrose.com, Telefon: +41 52 724 08 14
Agenda
20. Oktober 2022 Q3/2022 Trading Update
19. Januar 2023 Umsatz 2022
23. März 2023 Jahresergebnis 2022
20. April 2023 Q1/2023 Trading Update
4. Mai 2023 Ordentliche Generalversammlung
Zur Rose-Gruppe
Die Schweizer Zur Rose-Gruppe ist Europas grösste E-Commerce-Apotheke und eine
der führenden Ärztegrossistinnen in der Schweiz. Darüber hinaus betreibt sie
den in Südeuropa führenden Marktplatz für apothekenübliche Gesundheits- und
Pflegeprodukte. Das Unternehmen ist international mit starken Marken präsent,
unter anderem mit Deutschlands bekanntester Apothekenmarke DocMorris. Zur Rose
beschäftigt an ihren Standorten in der Schweiz, Deutschland, den Niederlanden,
Spanien und Frankreich über 2'400 Mitarbeiter. Im Jahr 2021 erwirtschaftete sie
einen Aussenumsatz von 2'034 Millionen Franken bei derzeit über 11 Millionen
aktiven Kunden in Kernmärkten Europas.
Mit ihrem Geschäftsmodell bietet die Zur Rose-Gruppe eine qualitativ
hochwertige, sichere und kostengünstige pharmazeutische Versorgung sowie
digitale Services im Bereich Marktplatz, Ökosystem, Technologie und
Telemedizin. Darüber hinaus treibt Zur Rose die Positionierung als umfassende
Gesundheitsdienstleisterin aktiv voran. Im Zentrum steht der Auf- und Ausbau
des europäischen Gesundheitsökosystems, auf welchem sich qualifizierte Anbieter
mit Produkten, Dienstleistungen und digitalen Lösungen vernetzen. Der Anspruch
von Zur Rose ist es, kundenzentrierte Behandlungspfade anzubieten, damit
Menschen eine optimale Versorgung sowie Medikations- und Therapieoptionen
erhalten. Zur Rose verfolgt damit die Vision, eine Welt zu schaffen, in der die
Menschen die eigene Gesundheit mit nur einem Klick managen können.
Die Aktien der Zur Rose Group AG sind an der SIX Swiss Exchange kotiert (Valor
4261528, ISIN CH0042615283, Ticker ROSE). Weitere Informationen unter
zurrosegroup.com.
Disclaimer
THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE
RESPONSIBILITY OF ZUR ROSE GROUP AG (THE "COMPANY") AND ZUR ROSE FINANCE B.V.
(THE "ISSUER"). THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR
BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO
RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION
CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.
THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR
PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA, CANADA,
ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH
OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE
THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED
OR PROHIBITED BY LAW,
THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE
DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.
THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN
JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER
INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE
SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE
A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE
COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN
PARTICULAR, THE SECURITIES OF THE COMPANY AND THE ISSUER REFERRED TO HEREIN MAY
NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US
SECURITIES ACT OF 1933 (THE "SECURITIES ACT") OR OFFERED IN A TRANSACTION
EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED
UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA,
CANADA OR JAPAN. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO
HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR
FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN "OFFSHORE TRANSACTION" IN
ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT OR FOR THE ACCOUNT OR
BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN.
THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO THE SWISS FEDERAL
ACT ON FINANCIAL SERVICES.
IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM
(EACH, A "RELEVANT STATE"), THIS ANNOUNCEMENT AND ANY OFFER IF MADE
SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN
THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129)
("QUALIFIED INVESTORS"). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED
EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN
MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL
SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE
"ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND
(III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, AND ANY INVESTMENT
ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH PERSONS AND IT
SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.
THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE,
"FORWARD-LOOKING STATEMENTS". THESE FORWARD-LOOKING STATEMENTS MAY BE
IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS
"BELIEVES", "ESTIMATES", "PLANS", "PROJECTS", "ANTICIPATES", "EXPECTS",
"INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE, THEIR NEGATIVE OR OTHER
VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS,
OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY
AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY FORWARD-LOOKING
STATEMENTS REFLECT THE ISSUER'S OR THE COMPANY'S CURRENT VIEW WITH RESPECT TO
FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER
RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP'S BUSINESS, RESULTS
OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES.
FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE. EACH OF THE
ISSUER, THE COMPANY, THE JOINT BOOKRUNNERS AND THEIR RESPECTIVE AFFILIATES
EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE
ANY FORWARD LOOKING STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A
RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.
THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR NOTICE WITHIN
THE MEANING OF THE ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL SERVICES
ACT OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE APPLICABLE LISTING RULES
OF ANY STOCK EXCHANGE. ANY PURCHASE OF BONDS OF THE ISSUER IN THE PROPOSED
OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF THE INFORMATION CONTAINED IN THE
FINAL PROSPECTUS TO BE ISSUED BY THE ISSUER IN CONNECTION WITH THE OFFERING.
ANY PURCHASE OF SHARES OF THE COMPANY IN THE PROPOSED OFFERING SHOULD BE MADE
SOLELY ON THE BASIS OF PUBLICLY AVAILABLE INFORMATION. THE INFORMATION IN THIS
ANNOUNCEMENT IS SUBJECT TO CHANGE THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY
FOR ISSUER AND THE COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING.
THEY WILL NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE CLIENTS IN RELATION
TO THE OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE
COMPANY FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR
FOR PROVIDING ADVICE IN RELATION TO THE OFFERING, THE CONTENTS OF THIS
ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO
HEREIN.
IN CONNECTION WITH THE OFFERING OF THE BONDS AND THE SHARES, THE JOINT
BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A PORTION OF THE SECURITIES
IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY, MAY RETAIN,
PURCHASE, SELL, OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH SECURITIES AND OTHER
SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED INVESTMENTS IN CONNECTION
WITH THE OFFERINGS OR OTHERWISE. ACCORDINGLY, REFERENCES IN THE PROSPECTUS
RELATED TO THE BONDS, ONCE PUBLISHED, BEING ISSUED, OFFERED, SUBSCRIBED,
ACQUIRED, PLACED OR OTHERWISE DEALT IN SHOULD BE READ AS INCLUDING ANY ISSUE OR
OFFER TO, OR SUBSCRIPTION, ACQUISITION, PLACING OR DEALING BY THE JOINT
BOOKRUNNERS AND ANY OF THEIR AFFILIATES ACTING IN SUCH CAPACITY. IN ADDITION,
THE JOINT BOOKRUNNERS, AND ANY OF THEIR AFFILIATES MAY ENTER INTO FINANCING
ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH
INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR
AFFILIATES MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES OF THE
ISSUER OR THE COMPANY. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE
EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH
ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.
NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS,
EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR LIABILITY
WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS
TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT
(OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE ANNOUNCEMENT) OR ANY
OTHER INFORMATION RELATING TO THE ISSUER OR THE COMPANY, THEIR SUBSIDIARIES OR
ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELECTRONIC FORM,
AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING
FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN
CONNECTION THEREWITH.
NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS
OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN
ANY JURISDICTION. ANY OFFER TO ACQUIRE SECURITIES PURSUANT TO THE PROPOSED
OFFERING WILL BE MADE. ANY INVESTOR SHOULD MAKE HIS INVESTMENT DECISION FOR THE
PURCHASE OF THE SHARES ON PUBLICLY AVAILABLE INFORMATION AND FOR THE PURCHASE
OF THE BONDS SOLELY ON THE BASIS OF THE INFORMATION THAT IS CONTAINED IN THE
PROSPECTUS (THE "PROSPECTUS") PUBLISHED BY THE COMPANY AND THE ISSUER IN
CONNECTION WITH THE OFFERING AND ADMISSION TO TRADING AND LISTING OF THE BONDS
TO BE ISSUED BY THE ISSUER AS DESCRIBED IN THE PROSPECTUS ON THE SIX SWISS
EXCHANGE. COPIES OF THE PROSPECTUS ARE AVAILABLE FREE OF CHARGE AT [ZUR ROSE
GROUP AG, LISA LÜTHI, CORPORATE COMMUNICATIONS, WALZMÜHLESTRASSE 60, 8500
FRAUENFELD, SWITZERLAND (TELEPHONE NUMBER: +41 (0)52 724 08 14; EMAIL:
LISA.LUETHI@ZURROSE.COM), AND AT UBS AG, PROSPECTUS LIBRARY, P.O. BOX, CH-8098
ZURICH (TELEPHONE NUMBER: +41 (0)44 239 47 03, FACSIMILE: +41 (0)44 239 69 14
OR EMAIL: SWISS-PROSPECTUS@UBS.COM), DURING REGULAR BUSINESS HOURS].
------------------------------------------------------------
Ende der Medienmitteilungen
------------------------------------------------------------
Sprache: Deutsch
Unternehmen: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Schweiz
Telefon: +41 52 724 08 14
Internet: www.zurrosegroup.com
ISIN: CH0042615283
Börsen: SIX Swiss Exchange
EQS News ID: 1440897
Ende der Mitteilung EQS News-Service
------------------------------------------------------------
1440897 13.09.2022 CET/CEST
